Insulin, Isophane

Summary

Insulin, Isophane (CHEMBL2108964) is a phase-3 clinical-stage protein targeting INSR; indicated across 4 conditions including type 1 diabetes mellitus and diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 1 (INSR)
• Indications: 4 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108964
Name	Insulin, Isophane
Type	Protein
Max phase	3

Also known as: Ins hum insulat, Ins hum protaphane, Ins humulin i, Ins hypurin bov isop, Ins hypurin pore isop, Ins innolet insulat, Ins insulat, Ins insulat novolet, Ins insuman basal, Ins insuman basal optiset, Ins insuman basal solostar, Ins novolet hum protaphane

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
INSR	Insulin receptor	Agonist		0.8%	P06213

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): INSR.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	1	INSR
Signal Transduction	1	INSR
Negative regulation of the PI3K/AKT network	1	INSR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	INSR
IRS activation	1	INSR
Signal attenuation	1	INSR
Insulin receptor signalling cascade	1	INSR
Signaling by Insulin receptor	1	INSR
Insulin receptor recycling	1	INSR
Intracellular signaling by second messengers	1	INSR
Signaling by Receptor Tyrosine Kinases	1	INSR

Dominant GO biological processes

GO term	Targets
positive regulation of receptor internalization	1
heart morphogenesis	1
regulation of DNA-templated transcription	1
receptor-mediated endocytosis	1
G protein-coupled receptor signaling pathway	1
learning	1
memory	1
positive regulation of cell population proliferation	1
insulin receptor signaling pathway	1
epidermis development	1
male gonad development	1
male sex determination	1
adrenal gland development	1
positive regulation of cell migration	1
exocrine pancreas development	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 1 diabetes mellitus	3	MONDO:0005147	MONDO:0005147
diabetes mellitus	1	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01963728	PHASE4	TERMINATED	Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
NCT04781751	Not specified	UNKNOWN	Ultrasonographic Insulin Versus Dexamethasone Injection With Local Anestheticss in Diabetic Patients With Mild to Moderate Median Nerve Entrapement Neuropathy .
NCT06055829	Not specified	COMPLETED	The Adjustment of Doses in Diabetes Mellitus Type I
NCT06173934	Not specified	UNKNOWN	The Effect of Gastric Emptying on Blood Glucose Profile of Type 1 Diabetes Mellitus and Its Therapeutic Strategies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

37 molecules share ≥1 primary target. Top 37 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	INSR
BRIGATINIB	ChEMBL	Phase 4 (approved)	INSR
CERITINIB	ChEMBL	Phase 4 (approved)	INSR
ENTRECTINIB	ChEMBL	Phase 4 (approved)	INSR
FEDRATINIB	ChEMBL	Phase 4 (approved)	INSR
INFIGRATINIB	ChEMBL	Phase 4 (approved)	INSR
LAPATINIB	ChEMBL	Phase 4 (approved)	INSR
NERATINIB	ChEMBL	Phase 4 (approved)	INSR
NINTEDANIB	ChEMBL	Phase 4 (approved)	INSR
OSIMERTINIB	ChEMBL	Phase 4 (approved)	INSR
SORAFENIB	ChEMBL	Phase 4 (approved)	INSR
SUNITINIB	ChEMBL	Phase 4 (approved)	INSR
DOVITINIB	ChEMBL	Phase 3	INSR
LESTAURTINIB	ChEMBL	Phase 3	INSR
LINIFANIB	ChEMBL	Phase 3	INSR
LINSITINIB	ChEMBL	Phase 3	INSR
BMS-754807	ChEMBL	Phase 2	INSR
CENISERTIB	ChEMBL	Phase 2	INSR
ELLAGIC ACID	ChEMBL	Phase 2	INSR
FORETINIB	ChEMBL	Phase 2	INSR
ILORASERTIB	ChEMBL	Phase 2	INSR
OSI-632	ChEMBL	Phase 2	INSR
R-406	ChEMBL	Phase 2	INSR
SU-014813	ChEMBL	Phase 2	INSR
TOZASERTIB	ChEMBL	Phase 2	INSR
Afatinib	PubChem	Approved	INSR
belumosudil	PubChem	Approved	INSR
Belzutifan	PubChem	Approved	INSR
Binimetinib	PubChem	Approved	INSR
dacomitinib	PubChem	Approved	INSR
Fostamatinib	PubChem	Approved	INSR
Gefitinib	PubChem	Approved	INSR
Idelalisib	PubChem	Approved	INSR
Pazopanib	PubChem	Approved	INSR
regorafenib	PubChem	Approved	INSR
Selumetinib	PubChem	Approved	INSR
Trametinib	PubChem	Approved	INSR